Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 16 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Adebrelimab | Phase 3 | Phase 3 | 120 | 62 | 8 | 144 | 0 | — | — | Jun 1, 2017 |
| Camrelizumab | Phase 3 | Phase 3 | 82 | 43 | 33 | 276 | 0 | — | — | Apr 6, 2016 |
| FOLFOX Regimen | Phase 3 | Phase 3 | 53 | 34 | 40 | 162 | 0 | — | — | 1998-01 |
| Disitamab Vedotin | Phase 3 | Phase 3 | 46 | 27 | 9 | 58 | 0 | — | — | Sep 26, 2018 |
| Immunotherapy | Phase 3 | Phase 3 | 41 | 28 | 13 | 61 | 0 | — | — | Jan 1, 2002 |
| CAPOX Regimen | Phase 3 | Phase 3 | 36 | 21 | 19 | 63 | 0 | — | — | 2002-08 |
| FOLFIRI Regimen | Phase 3 | Phase 3 | 29 | 17 | 36 | 134 | 0 | — | — | 1998-01 |
| Ipatasertib | Phase 3 | Phase 3 | 21 | 7 | 5 | 50 | 0 | — | — | 2010-03 |
| Ipilimumab/Nivolumab Regimen | Phase 3 | Phase 3 | 19 | 8 | 6 | 36 | 0 | — | — | 2012-12 |
| Immunomodulatory Oligonucleotide | Phase 3 | Phase 3 | 18 | 9 | 4 | 36 | 0 | — | — | 2004-06 |
| Anti-PD1 Monoclonal Antibody | Phase 3 | Phase 3 | 18 | 15 | 1 | 32 | 0 | — | — | Sep 30, 2018 |
| Cediranib | Phase 3 | Phase 3 | 17 | 2 | 10 | 100 | 0 | — | — | 2003-02 |
| Copanlisib | Phase 3 | Phase 3 | 15 | 0 | 3 | 70 | 0 | — | — | Nov 19, 2009 |
| Omacetaxine Mepesuccinate | Phase 3 | Phase 3 | 15 | 10 | 6 | 34 | 0 | — | — | 1994-09 |
| Patritumab Deruxtecan | Phase 3 | Phase 3 | 14 | 10 | 2 | 20 | 0 | — | — | Nov 28, 2016 |
| Veliparib | Phase 3 | Phase 3 | 13 | 1 | 6 | 96 | 0 | — | — | 2006-06 |
| Savolitinib | Phase 3 | Phase 3 | 13 | 3 | 5 | 34 | 0 | — | — | 2012-02 |
| Sunvozertinib | Phase 3 | Phase 3 | 12 | 8 | 2 | 13 | 0 | — | — | Jul 9, 2019 |
| Hyperthermic Intraperitoneal Chemotherapy | Phase 3 | Phase 3 | 11 | 4 | 5 | 20 | 0 | — | — | 2009-05 |
| Divarasib | Phase 3 | Phase 3 | 10 | 6 | 5 | 11 | 0 | — | — | Sep 22, 2017 |
| Dabrafenib/Trametinib Regimen | Phase 3 | Phase 3 | 8 | 7 | 1 | 13 | 0 | — | — | 2014-10 |
| Radiation Therapy | Phase 3 | Phase 3 | 7 | 3 | 2 | 14 | 0 | — | — | 2001-02 |
| Alisertib | Phase 3 | Phase 3 | 6 | 3 | 1 | 60 | 0 | — | — | May 15, 2007 |
| Pegargiminase | Phase 3 | Phase 3 | 6 | 3 | 4 | 33 | 0 | — | — | 2001-09 |
| Guadecitabine | Phase 3 | Phase 3 | 6 | 0 | 2 | 27 | 0 | — | — | Jan 4, 2011 |
| Abexinostat | Phase 3 | Phase 3 | 6 | 3 | 1 | 14 | 0 | — | — | 2005-08 |
| Daromun | Phase 3 | Phase 3 | 6 | 5 | 2 | 9 | 0 | — | — | 2012-12 |
| Navtemadlin | Phase 3 | Phase 3 | 5 | 2 | 1 | 18 | 0 | — | — | Dec 27, 2012 |
| Niacinamide | Phase 3 | Phase 3 | 5 | 5 | 2 | 10 | 0 | — | — | 2008-06 |
| Safusidenib | Phase 3 | Phase 3 | 5 | 1 | 2 | 6 | 0 | — | — | Jan 19, 2017 |
| Amrubicin | Phase 3 | Phase 3 | 4 | 3 | 8 | 22 | 0 | — | — | 2004-05 |
| Durvalumab/Tremelimumab Regimen | Phase 3 | Phase 3 | 4 | 1 | 1 | 14 | 0 | — | — | Nov 3, 2015 |
| Chemoradiotherapy | Phase 3 | Phase 3 | 4 | 4 | 3 | 10 | 0 | — | — | 2005-09 |
| HyperCVAD Regimen | Phase 3 | Phase 3 | 4 | 3 | 1 | 5 | 0 | — | — | 2010-07 |
| Tipifarnib | Phase 3 | Phase 3 | 3 | 1 | 2 | 78 | 0 | — | — | 1998-10 |
| Fexagratinib | Phase 3 | Phase 3 | 3 | 0 | 1 | 15 | 0 | — | — | Oct 21, 2009 |
| Tyrosine Kinase Inhibitor | Phase 3 | Phase 3 | 3 | 2 | 2 | 11 | 0 | — | — | Aug 8, 2012 |
| Setidegrasib | Phase 3 | Phase 3 | 3 | 3 | 2 | 3 | 0 | — | — | Jun 8, 2022 |
| Ganitumab | Phase 3 | Phase 3 | 2 | 1 | 2 | 26 | 0 | — | — | 2005-10 |
| Dinaciclib | Phase 3 | Phase 3 | 2 | 0 | 1 | 18 | 0 | — | — | 2006-08 |
| Donor Lymphocyte Infusion | Phase 3 | Phase 3 | 2 | 2 | 3 | 12 | 0 | — | — | 2010-02 |
| Taselisib | Phase 3 | Phase 3 | 2 | 0 | 1 | 10 | 0 | — | — | Mar 16, 2011 |
| TAK-788 | Phase 3 | Phase 3 | 2 | 0 | 1 | 4 | 0 | — | — | Jun 16, 2016 |
| Ganetespib | Phase 3 | Phase 3 | 1 | 1 | 1 | 31 | 0 | — | — | 2007-10 |
| O6-Benzylguanine | Phase 3 | Phase 3 | 1 | 1 | 1 | 29 | 0 | — | — | 1996-01 |
| Barasertib | Phase 3 | Phase 3 | 1 | 0 | 1 | 12 | 0 | — | — | 2005-05 |
| Hematopoietic Cell Transplantation | Phase 3 | Phase 3 | 1 | 0 | 1 | 12 | 0 | — | — | Nov 18, 1999 |
| Rogaratinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 10 | 0 | — | — | Dec 30, 2013 |
| Cyproterone Acetate | Phase 3 | Phase 3 | 1 | 1 | 6 | 9 | 0 | — | — | 1987-05 |
| Galeterone | Phase 3 | Phase 3 | 1 | 0 | 1 | 4 | 0 | — | — | 2009-10 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.